| Product Code: ETC9959138 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Sumit Sagar | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Overview |
3.1 United States (US) Country Macro Economic Indicators |
3.2 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, 2021 & 2031F |
3.3 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market - Industry Life Cycle |
3.4 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market - Porter's Five Forces |
3.5 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume Share, By Drugs, 2021 & 2031F |
3.6 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume Share, By Gene Type, 2021 & 2031F |
3.7 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.8 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume Share, By End User, 2021 & 2031F |
3.9 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing awareness about alpha-1 antitrypsin deficiency (AATD) among healthcare professionals and patients |
4.2.2 Growing prevalence of AATD in the United States |
4.2.3 Technological advancements in AATD augmentation therapy |
4.3 Market Restraints |
4.3.1 High cost associated with AATD augmentation therapy |
4.3.2 Limited reimbursement options for AATD treatments |
4.3.3 Stringent regulatory requirements for approval of AATD therapies |
5 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Trends |
6 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market, By Types |
6.1 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market, By Drugs |
6.1.1 Overview and Analysis |
6.1.2 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Drugs, 2021- 2031F |
6.1.3 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Prolastin, 2021- 2031F |
6.1.4 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Zemaira/Respreeza, 2021- 2031F |
6.1.5 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Glassia, 2021- 2031F |
6.1.6 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Aralast NP, 2021- 2031F |
6.1.7 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Others, 2021- 2031F |
6.2 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market, By Gene Type |
6.2.1 Overview and Analysis |
6.2.2 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Type PiZZ, 2021- 2031F |
6.2.3 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Type PiMS, 2021- 2031F |
6.2.4 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Type PiMZ, 2021- 2031F |
6.2.5 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Others, 2021- 2031F |
6.3 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market, By Application |
6.3.1 Overview and Analysis |
6.3.2 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Lung Disease, 2021- 2031F |
6.3.3 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Liver Disease, 2021- 2031F |
6.3.4 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Population Type, 2021- 2031F |
6.3.5 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Adults and Pediatric, 2021- 2031F |
6.4 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market, By End User |
6.4.1 Overview and Analysis |
6.4.2 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.4.3 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.4.4 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Home Healthcare, 2021- 2031F |
6.4.5 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Others, 2021- 2031F |
6.5 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market, By Distribution Channel |
6.5.1 Overview and Analysis |
6.5.2 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.5.3 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
6.5.4 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Online Pharmacy, 2021- 2031F |
6.5.5 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Others, 2021- 2031F |
7 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Import-Export Trade Statistics |
7.1 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Export to Major Countries |
7.2 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Imports from Major Countries |
8 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Key Performance Indicators |
8.1 Patient adherence rate to AATD augmentation therapy |
8.2 Number of clinical trials evaluating new AATD therapies |
8.3 Healthcare provider education and training initiatives on AATD management |
9 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market - Opportunity Assessment |
9.1 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Opportunity Assessment, By Drugs, 2021 & 2031F |
9.2 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Opportunity Assessment, By Gene Type, 2021 & 2031F |
9.3 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Opportunity Assessment, By Application, 2021 & 2031F |
9.4 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Opportunity Assessment, By End User, 2021 & 2031F |
9.5 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market - Competitive Landscape |
10.1 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenue Share, By Companies, 2024 |
10.2 United States (US) Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here